These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 11880163)

  • 1. Treatment with glatiramer acetate induces specific IgG4 antibodies in multiple sclerosis patients.
    Farina C; Vargas V; Heydari N; Kümpfel T; Meinl E; Hohlfeld R
    J Neuroimmunol; 2002 Feb; 123(1-2):188-92. PubMed ID: 11880163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A differential sex-specific pattern of IgG2 and IgG4 subclasses of anti-drug antibodies (ADAs) induced by glatiramer acetate in relapsing-remitting multiple sclerosis patients.
    Avila S; Guerrero-García JJ; Becerril-Villanueva E; Pérez-Sánchez G; Pavón L; Rojas-Mayorquín AE; Mireles-Ramírez MA; Muñoz-Valle JF; Vallejo-Castillo L; Medina-Rivero E; Ortuño-Sahagún D; Pérez-Tapia SM
    Mult Scler Relat Disord; 2019 Sep; 34():92-99. PubMed ID: 31272071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glatiramer acetate immunization induces specific antibody and cytokine responses in ALS patients.
    Mosley RL; Gordon PH; Hasiak CM; Van Wetering FJ; Mitsumoto H; Gendelman HE
    Amyotroph Lateral Scler; 2007 Aug; 8(4):235-42. PubMed ID: 17653922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. During 3 years treatment of primary progressive multiple sclerosis with glatiramer acetate, specific antibodies switch from IgG1 to IgG4.
    Basile E; Gibbs E; Aziz T; Oger J
    J Neuroimmunol; 2006 Aug; 177(1-2):161-6. PubMed ID: 16765453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glatiramer acetate-specific antibody titres in patients with relapsing / remitting multiple sclerosis and in experimental autoimmune encephalomyelitis.
    Bomprezzi R; Schaefer R; Reese V; Misra A; Vollmer TL; Kala M
    Scand J Immunol; 2011 Sep; 74(3):219-226. PubMed ID: 21615449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term treatment of multiple sclerosis with glatiramer acetate: natural history of the subtypes of anti-glatiramer acetate antibodies and their correlation with clinical efficacy.
    Karussis D; Teitelbaum D; Sicsic C; Brenner T;
    J Neuroimmunol; 2010 Mar; 220(1-2):125-30. PubMed ID: 20153903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glatiramer acetate antibodies, gene expression and disease activity in multiple sclerosis.
    Sellebjerg F; Hedegaard CJ; Krakauer M; Hesse D; Lund H; Nielsen CH; Søndergaard HB; Sørensen PS
    Mult Scler; 2012 Mar; 18(3):305-13. PubMed ID: 22020419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Humoral and cellular immune responses to Copolymer 1 in multiple sclerosis patients treated with Copaxone.
    Brenner T; Arnon R; Sela M; Abramsky O; Meiner Z; Riven-Kreitman R; Tarcik N; Teitelbaum D
    J Neuroimmunol; 2001 Apr; 115(1-2):152-60. PubMed ID: 11282165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis.
    Duda PW; Schmied MC; Cook SL; Krieger JI; Hafler DA
    J Clin Invest; 2000 Apr; 105(7):967-76. PubMed ID: 10749576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serial combination therapy: is immune modulation in multiple sclerosis enhanced by initial immune suppression?
    Bar-Or A; Oger J; Gibbs E; Niino M; Aziz T; Renoux C; Alatab S; Shi FD; Campagnolo D; Jalili F; Rhodes S; Yamashita T; Fan B; Freedman MS; Panitch H; Arnold DL; Vollmer T
    Mult Scler; 2009 Aug; 15(8):959-64. PubMed ID: 19667022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic induction of regulatory, cytotoxic CD8+ T cells in multiple sclerosis.
    Tennakoon DK; Mehta RS; Ortega SB; Bhoj V; Racke MK; Karandikar NJ
    J Immunol; 2006 Jun; 176(11):7119-29. PubMed ID: 16709875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of T cell lines derived from glatiramer-acetate-treated multiple sclerosis patients.
    Qin Y; Zhang DQ; Prat A; Pouly S; Antel J
    J Neuroimmunol; 2000 Aug; 108(1-2):201-6. PubMed ID: 10900354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibodies to glatiramer acetate do not interfere with its biological functions and therapeutic efficacy.
    Teitelbaum D; Brenner T; Abramsky O; Aharoni R; Sela M; Arnon R
    Mult Scler; 2003 Dec; 9(6):592-9. PubMed ID: 14664472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glatiramer acetate (Copaxone) therapy induces CD8(+) T cell responses in patients with multiple sclerosis.
    Karandikar NJ; Crawford MP; Yan X; Ratts RB; Brenchley JM; Ambrozak DR; Lovett-Racke AE; Frohman EM; Stastny P; Douek DC; Koup RA; Racke MK
    J Clin Invest; 2002 Mar; 109(5):641-9. PubMed ID: 11877472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple sclerosis: expression of CD1a and production of IL-12p70 and IFN-gamma by blood mononuclear cells in patients on combination therapy with IFN-beta and glatiramer acetate compared to monotherapy with IFN-beta.
    Hussien Y; Sanna A; Söderström M; Link H; Huang YM
    Mult Scler; 2004 Feb; 10(1):16-25. PubMed ID: 14760948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Type 2 monocyte and microglia differentiation mediated by glatiramer acetate therapy in patients with multiple sclerosis.
    Kim HJ; Ifergan I; Antel JP; Seguin R; Duddy M; Lapierre Y; Jalili F; Bar-Or A
    J Immunol; 2004 Jun; 172(11):7144-53. PubMed ID: 15153538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of serum IL-13 and IL-5 levels with clinical response to Glatiramer acetate in patients with multiple sclerosis.
    Wiesemann E; Klatt J; Wenzel C; Heidenreich F; Windhagen A
    Clin Exp Immunol; 2003 Sep; 133(3):454-60. PubMed ID: 12930374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple sclerosis: comparison of copolymer-1- reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells.
    Neuhaus O; Farina C; Yassouridis A; Wiendl H; Then Bergh F; Dose T; Wekerle H; Hohlfeld R
    Proc Natl Acad Sci U S A; 2000 Jun; 97(13):7452-7. PubMed ID: 10861011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glatiramer acetate induces a Th2-biased response and crossreactivity with myelin basic protein in patients with MS.
    Chen M; Gran B; Costello K; Johnson K; Martin R; Dhib-Jalbut S
    Mult Scler; 2001 Aug; 7(4):209-19. PubMed ID: 11548979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor.
    Ziemssen T; Kümpfel T; Klinkert WE; Neuhaus O; Hohlfeld R
    Brain; 2002 Nov; 125(Pt 11):2381-91. PubMed ID: 12390966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.